Fig. 2
From: CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
CMTM6 is upregulated in trastuzumab-resistant BC and correlates with poor prognosis. A qRT-PCR and B Western blot analyses of CMTM6 mRNA and protein expression in different BC cell lines. C Immunohistochemical analysis of CMTM6 protein expression in HER2+ BC tissues from trastuzumab-treated patients (scale bar, 50 μM). D Immunohistochemical analysis of CMTM6 protein expression in HER2+ BC tissues from trastuzumab-treated patients with or without relapse. E, F Kaplan–Meier analysis of overall survival (OS) and relapse-free survival (RFS) in trastuzumab-treated high or low CMTM6 expressing HER2+ BC patients